{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T07:12:06Z","timestamp":1794813126595,"version":"4.9.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Prostate cancer (PC) aetiology is unclear. PC risk was examined in relation to several factors in a large population-based prospective study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Male participants were from Sax Institute\u2019s 45 and Up Study (Australia) recruited between 2006 and 2009. Questionnaire and linked administrative health data from the Centre for Health Record Linkage and Services Australia were used to identify incident PC, healthcare utilisations, Prostate Specific Antigen (PSA) testing reimbursements and dispensing of metformin and benign prostatic hyperplasia (BPH) prescriptions. Multivariable Cox and Joint Cox regression analyses were used to examine associations by cancer spread, adjusting for various confounders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 107,706 eligible men, 4257 developed incident PC up to end 2013. Risk of PC diagnosis increased with: PC family history (versus no family history of cancer; HR<jats:sub>adjusted<\/jats:sub>\u2009=\u20091.36; 95% CI:1.21\u20131.52); father and brother(s) diagnosed with PC (versus cancer-free family history; HR<jats:sub>adjusted<\/jats:sub>\u2009=\u20092.20; 95% CI:1.61\u20132.99); severe lower-urinary-tract symptoms (versus mild; HR<jats:sub>adjusted<\/jats:sub>\u2009=\u20091.77; 95% CI:1.53\u20132.04) and vasectomy (versus none; HR<jats:sub>adjusted<\/jats:sub>\u2009=\u20091.08; 95% CI:1.00\u20131.16). PC risk decreased with dispensed prescriptions (versus none) for BPH (HR<jats:sub>adjusted<\/jats:sub>\u2009=\u20090.76; 95% CI:0.69\u20130.85) and metformin (HR<jats:sub>adjusted<\/jats:sub>\u2009=\u20090.57; 95% CI:0.48\u20130.68). Advanced PC risk increased with vasectomy (HR<jats:sub>adjusted<\/jats:sub>\u2009=\u20091.28; 95% CI:1.06\u20131.55) and being obese (versus normal weight; HR<jats:sub>adjusted<\/jats:sub>\u2009=\u20091.31; 95% CI:1.01\u20131.69).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Vasectomy and obesity are associated with an increased risk of advanced PC. The reduced risk of localised and advanced PC associated with BPH, and diabetes prescriptions warrants investigation.<\/jats:p><\/jats:sec>","DOI":"10.1038\/s41416-022-01827-1","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T19:02:43Z","timestamp":1653418963000},"page":"735-746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study"],"prefix":"10.1038","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6277-5125","authenticated-orcid":false,"given":"Visalini","family":"Nair-Shalliker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8638-7979","authenticated-orcid":false,"given":"Xue Qin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8154-6731","authenticated-orcid":false,"given":"Karen","family":"Chiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish I.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne L.","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce K.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1474-3214","authenticated-orcid":false,"given":"David P.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"1827_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pi\u00f1eros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941\u201353.","journal-title":"Int J Cancer"},{"key":"1827_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/ijc.10810","volume":"103","author":"GG Giles","year":"2003","unstructured":"Giles GG, Severi G, English DR, McCredie MR, MacInnis R, Boyle P, et al. Early growth, adult body size and prostate cancer risk. Int J Cancer. 2003;103:241\u20135.","journal-title":"Int J Cancer"},{"key":"1827_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/ijc.2910600315","volume":"60","author":"RB Hayes","year":"1995","unstructured":"Hayes RB, Liff JM, Pottern LM, Greenberg RS, Schoenberg JB, Schwartz AG, et al. Prostate cancer risk in U.S. blacks and whites with a family history of cancer. Int J Cancer. 1995;60:361\u20134.","journal-title":"Int J Cancer"},{"key":"1827_CR4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41416-020-0897-4","volume":"123","author":"J Hur","year":"2020","unstructured":"Hur J, Giovannucci E. Racial differences in prostate cancer: does timing of puberty play a role? Br J Cancer. 2020;123:349\u201354.","journal-title":"Br J Cancer"},{"key":"1827_CR5","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/bjc.2017.312","volume":"117","author":"A Perez-Cornago","year":"2017","unstructured":"Perez-Cornago A, Key TJ, Allen NE, Fensom GK, Bradbury KE, Martin RM, et al. Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study. Br J Cancer. 2017;117:1562\u201371.","journal-title":"Br J Cancer"},{"key":"1827_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/ijc.30471","volume":"140","author":"V Nair-Shalliker","year":"2017","unstructured":"Nair-Shalliker V, Yap S, Nunez C, Egger S, Rodger J, Patel MI. et al. Adult body size, sexual history and adolescent sexual development, may predict risk of developing prostate cancer: Results from the New South Wales Lifestyle and Evaluation of Risk Study (CLEAR). Int J Cancer. 2017;140:565\u201374.","journal-title":"Int J Cancer"},{"key":"1827_CR7","unstructured":"World Cancer Research Fund. Diet, Nutrition, Physical Activity and Cancer: a Global Perspective. https:\/\/www.wcrf.org\/diet-activity-and-cancer\/cancer-types\/prostate-cancer\/. Accessed May 2022."},{"key":"1827_CR8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/bjc.2011.319","volume":"105","author":"A Discacciati","year":"2011","unstructured":"Discacciati A, Orsini N, Andersson SO, Andr\u00e9n O, Johansson JE, Wolk A. Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study. Br J Cancer. 2011;105:1061\u20138.","journal-title":"Br J Cancer"},{"key":"1827_CR9","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1158\/1940-6207.CAPR-15-0141","volume":"8","author":"T Feng","year":"2015","unstructured":"Feng T, Sun X, Howard LE, Vidal AC, Gaines AR, Moreira DM, et al. Metformin use and risk of prostate cancer: results from the REDUCE study. Cancer Prev Res. 2015;8:1055\u201360.","journal-title":"Cancer Prev Res"},{"key":"1827_CR10","doi-asserted-by":"publisher","unstructured":"Feng, X, Song, M, Preston, MA, Ma, W, Hu, Y, Pernar, CH, et al. The association of diabetes with risk of prostate cancer defined by clinical and molecular features. Br J Cancer. 2020. https:\/\/doi.org\/10.1038\/s41416-020-0910-y.","DOI":"10.1038\/s41416-020-0910-y"},{"key":"1827_CR11","doi-asserted-by":"publisher","first-page":"e14955","DOI":"10.1097\/MD.0000000000014955","volume":"98","author":"Z Feng","year":"2019","unstructured":"Feng Z, Zhou X, Liu N, Wang J, Chen X, Xu X. Metformin use and prostate cancer risk: a meta-analysis of cohort studies. Medicine. 2019;98:e14955.","journal-title":"Medicine"},{"key":"1827_CR12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2174\/1381612825666190215123759","volume":"25","author":"B Ghiasi","year":"2019","unstructured":"Ghiasi B, Sarokhani D, Najafi F, Motedayen M, Dehkordi AH. The relationship between prostate cancer and metformin consumption: a systematic review and meta-analysis study. Curr Pharm Des. 2019;25:1021\u20139.","journal-title":"Curr Pharm Des"},{"key":"1827_CR13","unstructured":"Mayo Clinic Patient Care and Health Information. https:\/\/www.mayoclinic.org\/diseases-conditions\/benign-prostatic-hyperplasia\/diagnosis-treatment\/drc-20370093. Accessed April 2022."},{"key":"1827_CR14","doi-asserted-by":"publisher","first-page":"5622","DOI":"10.1158\/1078-0432.CCR-18-0420","volume":"24","author":"Q Liu","year":"2018","unstructured":"Liu Q, Tong D, Liu G, Gao J, Wang LA, Xu J, et al. Metformin inhibits prostate cancer progression by targeting tumor-associated inflammatory infiltration. Clin Cancer Res. 2018;24:5622\u201334.","journal-title":"Clin Cancer Res"},{"key":"1827_CR15","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1093\/jnci\/djt170","volume":"105","author":"D Margel","year":"2013","unstructured":"Margel D, Urbach D, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, et al. Association between metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst. 2013;105:1123\u201331.","journal-title":"J Natl Cancer Inst"},{"key":"1827_CR16","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/ijc.30480","volume":"140","author":"C H\u00e4ggstr\u00f6m","year":"2017","unstructured":"H\u00e4ggstr\u00f6m C, Van Hemelrijck M, Zethelius B, Robinson D, Grundmark B, Holmberg L, et al. Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer. Int J Cancer. 2017;140:611\u20137.","journal-title":"Int J Cancer"},{"key":"1827_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/21681805.2016.1271353","volume":"51","author":"A Haring","year":"2017","unstructured":"Haring A, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen A. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Scand J Urol. 2017;51:5\u201312.","journal-title":"Scand J Urol"},{"key":"1827_CR18","doi-asserted-by":"publisher","first-page":"e9282","DOI":"10.7717\/peerj.9282","volume":"8","author":"T Deng","year":"2020","unstructured":"Deng T, Lin X, Duan X, He Z, Zhao Z, Zeng G. Prostate cancer patients can benefit from 5-alpha-reductase inhibitor treatment: a meta-analysis. PeerJ. 2020;8:e9282.","journal-title":"PeerJ"},{"key":"1827_CR19","doi-asserted-by":"publisher","unstructured":"Jacobs EJ, Anderson RL, Stevens VL, Newton CC, Gansler T, Gapstur, SM. Vasectomy and Prostate Cancer Incidence and Mortality in a Large US Cohort. J Clin Oncol. 2016. https:\/\/doi.org\/10.1200\/JCO.2015.66.2361.","DOI":"10.1200\/JCO.2015.66.2361"},{"key":"1827_CR20","doi-asserted-by":"publisher","first-page":"52690","DOI":"10.18632\/oncotarget.17082","volume":"8","author":"WY Lin","year":"2017","unstructured":"Lin WY, Chang YH, Lin CL, Kao CH, Wu HC. Erectile dysfunction and the risk of prostate cancer. Oncotarget. 2017;8:52690\u20138.","journal-title":"Oncotarget"},{"key":"1827_CR21","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.eururo.2012.12.060","volume":"63","author":"CJ Weight","year":"2013","unstructured":"Weight CJ, Kim SP, Jacobson DJ, McGree ME, Boorjian SA, Thompson RH, et al. The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. Eur Urol. 2013;63:1021\u20137.","journal-title":"Eur Urol"},{"key":"1827_CR22","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/ajr.12504","volume":"27","author":"RJS Calopedos","year":"2019","unstructured":"Calopedos RJS, Bang A, Baade P, Yu XQ, Ruthven S, Patel MI, et al. Patterns of prostate-specific antigen testing by remoteness of residence and socio-economic status: an Australian population-based study. Aust J Rural Health. 2019;27:216\u201323.","journal-title":"Aust J Rural Health"},{"key":"1827_CR23","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1093\/ije\/dym184","volume":"37","author":"E Banks","year":"2008","unstructured":"Banks E, Redman S, Jorm L, Armstrong B, Bauman A, Beard J, et al. Cohort profile: the 45 and up study. Int J Epidemiol. 2008;37:941\u20137.","journal-title":"Int J Epidemiol"},{"key":"1827_CR24","unstructured":"Cancer Institute of New South Wales, Caveat on the use of data items https:\/\/www.cancer.nsw.gov.au\/getmedia\/1d6bf5fd-eea3-48a4-b800-."},{"key":"1827_CR25","unstructured":"Cancer Institute of New South Wales, NSW Cancer Registry data dictionary, https:\/\/www.cherel.org.au\/media\/38825\/nsw-cancer-registry-data-dictionary_may2015.pdf. Accessed May 2022."},{"key":"1827_CR26","first-page":"i","volume":"894","author":"WHO.","year":"2000","unstructured":"WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i\u2013xii. 1-253","journal-title":"World Health Organ Tech Rep Ser"},{"key":"1827_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1017\/S1368980010000674","volume":"14","author":"E Banks","year":"2011","unstructured":"Banks E, Jorm L, Rogers K, Clements M, Bauman A. Screen-time, obesity, ageing and disability: findings from 91 266 participants in the 45 and Up Study. Public Health Nutr. 2011;14:34\u201343.","journal-title":"Public Health Nutr"},{"key":"1827_CR28","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00345-012-0937-7","volume":"31","author":"I Latz","year":"2013","unstructured":"Latz I, Weber M, Korda R, Smith D, Clements M, Patel M, et al. Lower urinary tract symptoms in relation to region of birth in 95,393 men living in Australia: the 45 and Up Study. World J Urol. 2013;31:673\u201382.","journal-title":"World J Urol"},{"key":"1827_CR29","unstructured":"Prostate Cancer Foundation of Australia and CancerCouncil Australia. Prostate Cancer Foundation of Australia and Cancer Council Australia PSA Testing Guidelines Expert Advisory Panel. Draft clinical practice guidelines for PSA testing and early management of test-detected prostate cancer. 2016. https:\/\/www.cancer.org.au\/health-professionals\/clinical-practice-guidelines\/prostate-cancer. Accessed January 2022."},{"key":"1827_CR30","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/ijc.23591","volume":"123","author":"J Ahn","year":"2008","unstructured":"Ahn J, Moslehi R, Weinstein SJ, Snyder K, Virtamo J, Albanes D. Family history of prostate cancer and prostate cancer risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. Int J Cancer. 2008;123:1154\u20139.","journal-title":"Int J Cancer"},{"key":"1827_CR31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ijc.11466","volume":"107","author":"DW Bruner","year":"2003","unstructured":"Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer. 2003;107:797\u2013803.","journal-title":"Int J Cancer"},{"key":"1827_CR32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/00001648-199903000-00020","volume":"10","author":"AG Schuurman","year":"1999","unstructured":"Schuurman AG, Zeegers MP, Goldbohm RA, van den Brandt PA. A case-cohort study on prostate cancer risk in relation to family history of prostate cancer. Epidemiology. 1999;10:192\u20135.","journal-title":"Epidemiology"},{"key":"1827_CR33","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1158\/1055-9965.EPI-13-0568","volume":"23","author":"JB Hjelmborg","year":"2014","unstructured":"Hjelmborg JB, Scheike T, Holst K, Skytthe A, Penney KL, Graff RE, et al. The heritability of prostate cancer in the Nordic Twin Study of Cancer. Cancer Epidemiol Biomark Prev. 2014;23:2303\u201310.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1827_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jama.2015.17703","volume":"315","author":"LA Mucci","year":"2016","unstructured":"Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, et al. Familial risk and heritability of cancer among twins in nordic countries. JAMA. 2016;315:68\u201376.","journal-title":"JAMA"},{"key":"1827_CR35","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1200\/JCO.2013.54.8446","volume":"32","author":"MM Siddiqui","year":"2014","unstructured":"Siddiqui MM, Wilson KM, Epstein MM, Rider JR, Martin NE, Stampfer MJ, et al. Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study. J Clin Oncol. 2014;32:3033\u20138.","journal-title":"J Clin Oncol"},{"key":"1827_CR36","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1200\/JCO.2016.70.0062","volume":"35","author":"K Smith","year":"2017","unstructured":"Smith K, Byrne, Castano JM, Chirlaque MD, Lilja H, Agudo A, et al. Vasectomy and prostate cancer risk in the european prospective investigation into cancer and nutrition (EPIC). J Clin Oncol. 2017;35:1297\u2013303.","journal-title":"J Clin Oncol"},{"key":"1827_CR37","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1001\/jamainternmed.2017.2791","volume":"177","author":"B Bhindi","year":"2017","unstructured":"Bhindi B, Wallis CJD, Nayan M, Farrell AM, Trost LW, Hamilton RJ, et al. The association between vasectomy and prostate cancer: a systematic review and meta-analysis. JAMA Intern Med. 2017;177:1273\u201386.","journal-title":"JAMA Intern Med"},{"key":"1827_CR38","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/j.juro.2008.11.127","volume":"181","author":"P Abrams","year":"2009","unstructured":"Abrams P, Chapple C, Khoury S, Roehrborn C, de la Rosette J. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol. 2009;181:1779\u201387.","journal-title":"J Urol"},{"key":"1827_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21681805.2019.1703806","volume":"54","author":"J Chandra Engel","year":"2020","unstructured":"Chandra Engel J, Palsdottir T, Aly M, Egevad L, Gr\u00f6nberg H, Eklund M, et al. Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50-69 years with PSA \u22653\u2009ng\/ml. Scand J Urol. 2020;54:1\u20136.","journal-title":"Scand J Urol"},{"key":"1827_CR40","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/j.1464-410X.2008.07817.x","volume":"102","author":"SM Collin","year":"2008","unstructured":"Collin SM, Metcalfe C, Donovan J, Lane JA, Davis M, Neal D, et al. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. BJU Int. 2008;102:1400\u20136.","journal-title":"BJU Int"},{"key":"1827_CR41","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/ijc.23713","volume":"123","author":"RM Martin","year":"2008","unstructured":"Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI. Lower urinary tract symptoms and risk of prostate cancer: the HUNT 2 Cohort, Norway. Int J Cancer. 2008;123:1924\u20138.","journal-title":"Int J Cancer"},{"key":"1827_CR42","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","volume":"362","author":"GL Andriole","year":"2010","unstructured":"Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192\u2013202.","journal-title":"N Engl J Med"},{"key":"1827_CR43","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1200\/JCO.2006.07.6836","volume":"25","author":"IM Thompson","year":"2007","unstructured":"Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, et al. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol. 2007;25:3076\u201381.","journal-title":"J Clin Oncol"},{"key":"1827_CR44","doi-asserted-by":"crossref","unstructured":"Unger JM, Till C, Thompson IM, Tangen CM, Goodman PJ, Wright JD, et al. Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute. 2016;108:djw168:1-7.","DOI":"10.1093\/jnci\/djw168"},{"key":"1827_CR45","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/bju.14534","volume":"123","author":"MI Van Rompay","year":"2019","unstructured":"Van Rompay MI, Curtis Nickel J, Ranganathan G, Kantoff PW, Solomon K, et al. Impact of 5\u03b1-reductase inhibitor and \u03b1-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality. BJU Int. 2019;123:511\u20138.","journal-title":"BJU Int"},{"key":"1827_CR46","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/pcan.2012.40","volume":"16","author":"D Bansal","year":"2013","unstructured":"Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 2013;16:151\u2013158, s151.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1827_CR47","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.eururo.2014.04.027","volume":"66","author":"MA Preston","year":"2014","unstructured":"Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, et al. Metformin use and prostate cancer risk. Eur Urol. 2014;66:1012\u201320.","journal-title":"Eur Urol"},{"key":"1827_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-38285-w","volume":"9","author":"K He","year":"2019","unstructured":"He K, Hu H, Ye S, Wang H, Cui R, Yi L. The effect of metformin therapy on incidence and prognosis in prostate cancer: a systematic review and meta-analysis. Sci Rep. 2019;9:2218.","journal-title":"Sci Rep"},{"key":"1827_CR49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1749-6632.2011.06285.x","volume":"1243","author":"EJ Gallagher","year":"2011","unstructured":"Gallagher EJ, LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci. 2011;1243:54\u201368.","journal-title":"Ann N Y Acad Sci"},{"key":"1827_CR50","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/CEJ.0000000000000394","volume":"27","author":"MM Nguyen","year":"2018","unstructured":"Nguyen MM, Martinez JA, Hsu CH, Sokoloff M, Krouse RS, Gibson BA, et al. Bioactivity and prostate tissue distribution of metformin in a preprostatectomy prostate cancer cohort. Eur J Cancer Prev. 2018;27:557\u201362.","journal-title":"Eur J Cancer Prev"},{"key":"1827_CR51","unstructured":"U.S. National Library of Medicine, Database of privately and publicly funded clinical studies https:\/\/clinicaltrials.gov\/ct2\/results?recrs=&cond=Prostate+Cancer&term=metformin&cntry=&state=&city=&dist=. Accessed May 2022."},{"key":"1827_CR52","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1158\/1055-9965.EPI-20-1571","volume":"30","author":"K Chiam","year":"2021","unstructured":"Chiam K, Bang A, Patel MI, Nair-Shalliker V, O\u2019Connell DL, Smith DP. Characteristics associated with the use of diagnostic prostate biopsy and biopsy outcomes in Australian men. Cancer Epidemiol Biomark Prev. 2021;30:1735\u201343.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1827_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22589-y","volume":"8","author":"V Nair-Shalliker","year":"2018","unstructured":"Nair-Shalliker V, Bang A, Weber M, Goldsbury DE, Caruana M, Emery J, et al. Factors associated with prostate specific antigen testing in Australians: analysis of the New South Wales 45 and Up Study. Sci Rep. 2018;8:4261.","journal-title":"Sci Rep"},{"key":"1827_CR54","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/ijc.30052","volume":"139","author":"SE Bonn","year":"2016","unstructured":"Bonn SE, Sj\u00f6lander A, Tillander A, Wiklund F, Gr\u00f6nberg H, B\u00e4lter K. Body mass index in relation to serum prostate-specific antigen levels and prostate cancer risk. Int J Cancer. 2016;139:50\u201357.","journal-title":"Int J Cancer"},{"key":"1827_CR55","doi-asserted-by":"publisher","first-page":"e106677","DOI":"10.1371\/journal.pone.0106677","volume":"9","author":"MB Hu","year":"2014","unstructured":"Hu MB, Liu SH, Jiang HW, Bai PD, Ding Q. Obesity affects the biopsy-mediated detection of prostate cancer, particularly high-grade prostate cancer: a dose-response meta-analysis of 29,464 patients. PLoS ONE. 2014;9:e106677.","journal-title":"PLoS ONE"},{"key":"1827_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-10-26","volume":"10","author":"NM Mealing","year":"2010","unstructured":"Mealing NM, Banks E, Jorm LR, Steel DG, Clements MS, Rogers KD. Investigation of relative risk estimates from studies of the same population with contrasting response rates and designs. BMC Med Res Methodol. 2010;10:26.","journal-title":"BMC Med Res Methodol"},{"key":"1827_CR57","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00345-014-1426-y","volume":"33","author":"M Randazzo","year":"2015","unstructured":"Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Wyler SF, et al. Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau). World J Urol. 2015;33:1189\u201396.","journal-title":"World J Urol"},{"key":"1827_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-13-481","volume":"13","author":"EJ Comino","year":"2013","unstructured":"Comino EJ, Tran DT, Haas M, Flack J, Jalaludin B, Jorm L, et al. Validating self-report of diabetes use by participants in the 45 and Up Study: a record linkage study. BMC Health Serv Res. 2013;13:481.","journal-title":"BMC Health Serv Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01827-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01827-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01827-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T04:41:20Z","timestamp":1700628080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01827-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,9,1]]}},"alternative-id":["1827"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-01827-1","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,24]]},"assertion":[{"value":"12 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Individuals gave written informed consent to take part in the study, including consent for follow-up through repeated data collection and linkage of their data to population health databases. Ethical approval for the conduct of the 45 and Up Study was provided by the University of New South Wales Human Research Ethics Committee. Ethical approval for the present study was provided by the NSW Population & Health Services Research Ethics Committee (14\/CIPHS\/54).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}